{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:41:29Z","timestamp":1771623689832,"version":"3.50.1"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019446","name":"Medical and Health Science and Technology Development Project of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICI) have markedly improved the prognosis of numerous malignancies; however, they are also associated with a broad spectrum of immune-related adverse events, commonly affecting the thyroid, gastrointestinal tract, skin, among other organs. Pulmonary hypertension (PH) triggered by ICI, though infrequently documented, has come to be recognized and regarded with greater importance in recent years owing to its association with life-threatening outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a case of a 65-year-old male who developed severe pulmonary arterial hypertension (PAH) following treatment with the programmed cell death protein 1 inhibitor tislelizumab. Following the initiation of a triple combination targeted therapy for PAH comprising macitentan, riociguat, and treprostinil, the patient's condition improved significantly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ICI-associated PH is a rare yet highly fatal adverse event. To date, no specific diagnostic or treatment guidelines exist for this condition due to its rarity. Therefore, there is an urgent need for more case reports, shared experiences, and clinical research to assist clinicians in identifying optimal strategies for the diagnosis and management of this complication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1705102","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:33:35Z","timestamp":1768545215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Immune checkpoint inhibitor-associated pulmonary hypertension"],"prefix":"10.3389","volume":"12","author":[{"given":"Shanshan","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunquan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13455","DOI":"10.3390\/ijms252413455","article-title":"Lymphocyte involvement in the pathology of pulmonary arterial hypertension","volume":"25","author":"Tomaszewski","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.3390\/jcm9061966","article-title":"Overexpression of PD-1 on peripheral blood lymphocytes in patients with idiopathic pulmonary arterial hypertension and its association with high viral loads of Epstein-Barr virus and poor clinical parameters","volume":"9","author":"Tomaszewski","year":"2020","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1161\/CIRCRESAHA.117.312058","article-title":"Dominant role for regulatory T cells in protecting females against pulmonary hyper tension","volume":"122","author":"Tamosiuniene","year":"2018","journal-title":"Circ Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1161\/HYPERTENSIONAHA.123.22393","article-title":"PD-1\/PD-L1 provides protective role in hypoxia-induced pulmonary vascular remodeling","volume":"81","author":"Wang","year":"2024","journal-title":"Hypertension"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894020960967","article-title":"Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor","volume":"10","author":"Glick","year":"2020","journal-title":"Ther Pulm Circ"},{"key":"B6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00280-020-04142-9","article-title":"Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer","volume":"86","author":"Fournel","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/1120009X.2024.2349858","article-title":"Rare immune related adverse effect of pembrolizumab: pulmonary hypertension","volume":"37","author":"Acar","year":"2025","journal-title":"J Chemother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.14740\/jmc5115","article-title":"Pulmonary arterial hypertension in a patient with metastatic lung cancer on pembrolizumab: whom to blame?","volume":"16","author":"Chintalacheruvu","year":"2025","journal-title":"J Med Cases"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894021992236","article-title":"Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation","volume":"11","author":"Mylvaganam","year":"2021","journal-title":"Pulm Circ"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1007\/s00262-022-03208-2","article-title":"Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study","volume":"71","author":"Palassin","year":"2022","journal-title":"Cancer Immunol Immunother"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1705102\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:33:57Z","timestamp":1768545237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1705102\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":10,"alternative-id":["10.3389\/fcvm.2025.1705102"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1705102","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"1705102"}}